Ratings for QuidelOrtho (NASDAQ:QDEL) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Analysts have set 12-month price targets for QuidelOrtho, revealing an average target of $57.25, a high estimate of $61.00, and a low estimate of $50.00. Surpassing the previous average price target of $51.00, the current average has increased by 12.25%.

Analyzing Analyst Ratings: A Detailed Breakdown

The standing of QuidelOrtho among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of QuidelOrtho's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on QuidelOrtho analyst ratings.

Unveiling the Story Behind QuidelOrtho

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.

QuidelOrtho's Financial Performance

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Negative Revenue Trend: Examining QuidelOrtho's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -4.22% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: QuidelOrtho's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -23.19%, the company may encounter challenges in effective cost control.

Return on Equity (ROE): QuidelOrtho's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -4.56%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): QuidelOrtho's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.21%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.87.

How Are Analyst Ratings Determined?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.